We are pleased to announce that the PHAGE study has successfully reached database lock. This Phase 1b/2 clinical trial investigated the safety profile and microbiological activity of bacteriophage therapy in individuals with cystic fibrosis (CF) who are chronically colonized with Pseudomonas aeruginosa.

Led by Pranita Tamma, MD, MHS, University of Pennsylvania, and Robert Schooley, MD, University of California, San Diego, the trial enrolled 72 participants across 17 sites. Participants were randomized to receive either a single intravenous dose of a four-component bacteriophage cocktail or a placebo.

The data generated from the PHAGE study will deepen our understanding of optimal dosing strategies, safety considerations, and the expected microbiological responses associated with bacteriophage therapy. Importantly, these findings will guide the design of future clinical trials that aim to advance bacteriophage-based treatments for antimicrobial-resistant infections, extending beyond P. aeruginosa-related lung disease.

For additional details, consult the study record—and stay tuned for forthcoming results.